Author: DelveInsight

Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics’ pancreatic cancer a bust

Business Consultant, Pharma Consultant, Pharma news

Incyte meets endpoint in the second pivotal atopic dermatitis clinical trial A second phase 3 trial of Incyte’s ruxolitinib cream in...

Read More

Cardiovascular Disease: A major cause of health loss and a global burden

Business Consultant, Pharma Consultant, Snippets

Cardiovascular diseases (CVDs) are one of the leading causes of death and health loss in people in the US. As per a study by the National...

Read More

Promising therapies that might shift Wet Age-related Macular Degeneration Market in the next decade

Articles, Business Consultant, Pharma Consultant

With no effective cure in Wet Age-related macular degeneration (Wet AMD) treatment market, the need of new therapies that can not only slow...

Read More

Wet Age-Related Macular Degeneration: Unravelling the complex disease with comprehensive R&D

Articles, Business Consultant, Pharma Consultant

Nearly 11 million Americans are living with one or other type of Age-Related Macular degeneration (AMD), estimates BrightFocus foundation....

Read More

The epidemic now has a name: COVID-19

Articles, Business Consultant, Pharma Consultant

Amid the breakout in Wuhan, China, the novel coronavirus has managed to invade the other countries across the globe. Till now, almost 25...

Read More

Good news for Kite’s KTE-X19, and Aquestive’s Libervant; and a commercialization deal between ReForm Biologics, MilliporeSigma

Articles, Business Consultant, Pharma Consultant

FDA has accepted Biological License Application submitted by Kite for its CAR-T cell therapy- KTE-X19, for relapsed or refractory mantle...

Read More
Close